Elisabeth Kieninger1, Florian Singer2, Caroline Tapparel3, Marco P Alves1, Philipp Latzin1, Hui-Leng Tan4, Cara Bossley4, Carmen Casaulta2, Andrew Bush4, Jane C Davies4, Laurent Kaiser3, Nicolas Regamey5. 1. Division of Pediatric Respiratory Medicine, Department of Pediatrics, University Hospital, Bern, Switzerland; Department of Clinical Research, University of Bern, Bern, Switzerland. 2. Division of Pediatric Respiratory Medicine, Department of Pediatrics, University Hospital, Bern, Switzerland. 3. Laboratory of Virology, Division of Infectious Diseases and Division of Laboratory Medicine, University of Geneva Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland. 4. Department of Pediatric Respiratory Medicine, Royal Brompton Hospital, London, England. 5. Division of Pediatric Respiratory Medicine, Department of Pediatrics, University Hospital, Bern, Switzerland; Department of Clinical Research, University of Bern, Bern, Switzerland. Electronic address: nicolas.regamey@insel.ch.
Abstract
BACKGROUND: Rhinovirus (RV)-induced pulmonary exacerbations are common in cystic fibrosis (CF) and have been associated with impaired virus clearance by the CF airway epithelium in vitro. Here, we assess in vivo the association of RV prevalence and load with antiviral defense mechanisms, airway inflammation, and lung function parameters in children with CF compared with a control group and children with other chronic respiratory diseases. METHODS: RV presence and load were measured by real-time reverse transcription-polymerase chain reaction in BAL samples and were related to antiviral and inflammatory mediators measured in BAL and to clinical parameters. RESULTS: BAL samples were obtained from children with CF (n = 195), non-CF bronchiectasis (n = 40), or asthma (n = 29) and from a control group (n = 35) at a median (interquartile range [IQR]) age of 8.2 (4.0-11.7) years. RV was detected in 73 samples (24.4%). RV prevalence was similar among groups. RV load (median [IQR] x 10(3) copies/mL) was higher in children with CF (143.0 [13.1-1530.0]), especially during pulmonary exacerbations, compared with children with asthma (3.0 [1.3-25.8], P = .006) and the control group (0.5 [0.3-0.5], P < .001), but similar to patients with non-CF bronchiectasis (122.1 [2.7-4423.5], P = not significant). In children with CF, RV load was negatively associated with interferon (IFN)- b and IFN- l , IL-1ra levels, and FEV 1 , and positively with levels of the cytokines CXCL8 and CXCL10. CONCLUSIONS: RV load in CF BAL is high, especially during exacerbated lung disease. Impaired production of antiviral mediators may lead to the high RV burden in the lower airways of children with CF. Whether high RV load is a cause or a consequence of inflammation needs further investigation in longitudinal studies.
BACKGROUND: Rhinovirus (RV)-induced pulmonary exacerbations are common in cystic fibrosis (CF) and have been associated with impaired virus clearance by the CF airway epithelium in vitro. Here, we assess in vivo the association of RV prevalence and load with antiviral defense mechanisms, airway inflammation, and lung function parameters in children with CF compared with a control group and children with other chronic respiratory diseases. METHODS: RV presence and load were measured by real-time reverse transcription-polymerase chain reaction in BAL samples and were related to antiviral and inflammatory mediators measured in BAL and to clinical parameters. RESULTS: BAL samples were obtained from children with CF (n = 195), non-CF bronchiectasis (n = 40), or asthma (n = 29) and from a control group (n = 35) at a median (interquartile range [IQR]) age of 8.2 (4.0-11.7) years. RV was detected in 73 samples (24.4%). RV prevalence was similar among groups. RV load (median [IQR] x 10(3) copies/mL) was higher in children with CF (143.0 [13.1-1530.0]), especially during pulmonary exacerbations, compared with children with asthma (3.0 [1.3-25.8], P = .006) and the control group (0.5 [0.3-0.5], P < .001), but similar to patients with non-CF bronchiectasis (122.1 [2.7-4423.5], P = not significant). In children with CF, RV load was negatively associated with interferon (IFN)- b and IFN- l , IL-1ra levels, and FEV 1 , and positively with levels of the cytokines CXCL8 and CXCL10. CONCLUSIONS: RV load in CF BAL is high, especially during exacerbated lung disease. Impaired production of antiviral mediators may lead to the high RV burden in the lower airways of children with CF. Whether high RV load is a cause or a consequence of inflammation needs further investigation in longitudinal studies.
Authors: Lyndsey M Muehling; Ronald B Turner; Kenneth B Brown; Paul W Wright; James T Patrie; Sampo J Lahtinen; Markus J Lehtinen; William W Kwok; Judith A Woodfolk Journal: J Infect Dis Date: 2018-01-17 Impact factor: 5.226
Authors: N Dauletbaev; K Herscovitch; M Das; H Chen; J Bernier; E Matouk; J Bérubé; S Rousseau; L C Lands Journal: Br J Pharmacol Date: 2015-10 Impact factor: 8.739
Authors: Ixsy A Ramirez; Lindsay J Caverly; Lindsay L Caverly; Linda M Kalikin; Adam M Goldsmith; Toby C Lewis; David T Burke; John J LiPuma; Uma S Sajjan; Marc B Hershenson Journal: Ann Am Thorac Soc Date: 2014-05
Authors: Abigail R Berkebile; Jennifer A Bartlett; Mahmoud Abou Alaiwa; Steven M Varga; Ultan F Power; Paul B McCray Journal: Am J Respir Cell Mol Biol Date: 2020-01 Impact factor: 6.914
Authors: Sarmila Basnet; Yury A Bochkov; Rebecca A Brockman-Schneider; Ine Kuipers; Scott W Aesif; Daniel J Jackson; Robert F Lemanske; Carol Ober; Ann C Palmenberg; James E Gern Journal: Am J Respir Cell Mol Biol Date: 2019-10 Impact factor: 6.914
Authors: Thomas E Hadfield; Fergus Imrie; Andy Merritt; Kristian Birchall; Charlotte M Deane Journal: J Chem Inf Model Date: 2022-05-02 Impact factor: 6.162